Related Experiment Video
Updated: Apr 23, 2026
High-frequency Ultrasound Imaging of Mouse Cervical Lymph Nodes
Published on: July 25, 2015
Core needle biopsy is a safe and accurate initial diagnostic procedure for suspected lymphoma
Brian M Nguyen1, Chelsea Halprin1, Yuliya Olimpiadi1
1Division of Surgical Oncology, Department of Surgery, Harbor-UCLA Medical Center, 1000 West Carson Box 25, Torrance, CA 90502, USA.
Insights
Image-guided core needle biopsy (IGCNB) is a safe and effective initial diagnostic tool for lymphoma. This method accurately diagnoses lymphadenopathy, offering a viable alternative to excisional biopsy.
Area of Science:
- Oncology
- Diagnostic Imaging
- Pathology
Background:
- Excisional biopsy is the standard for diagnosing lymphoma in lymphadenopathy.
- There is a need for less invasive diagnostic methods.
Purpose of the Study:
- To evaluate the efficacy and safety of image-guided core needle biopsy (IGCNB) for lymphoma diagnosis.
- To establish IGCNB as an initial diagnostic tool for lymphadenopathy.
Main Methods:
- Retrospective analysis of 73 IGCNBs performed between 2008 and 2014.
- Data collected included demographics, pathology results, and follow-up information.
Main Results:
- Lymphoma was diagnosed in 51% of patients (37/71).
- All diagnosed lymphomas were subtyped and treated based on IGCNB results.
- No complications were reported during the procedures.
Conclusions:
- IGCNB is an effective and safe initial diagnostic tool for lymphoma.
- Standardized protocols for IGCNB enhance diagnostic accuracy.
- IGCNB should be considered for evaluating lymphadenopathy suspicious for lymphoma.
Background:
Excisional biopsy is currently recommended for the analysis of lymphadenopathy suspicious for lymphoma. This study aims to evaluate the efficacy and safety of image-guided core needle biopsy (IGCNB) for the diagnosis of lymphoma using a standard protocol for tissue acquisition and analysis.
Methods:
All IGCNBs from 2008 to 2014 performed under the study protocol were included in analysis. Demographics, pathology results, additional studies, and follow-up information were recorded.
Results:
Seventy-three IGCNBs were performed in 71 consecutive patients. Lymphoma was diagnosed in 37 patients (51%). All 37 patients (100%) were subtyped and treated based on IGCNB results. The remaining 36 IGCNBs in 34 patients did not have subsequent diagnosis of lymphoma in a mean follow-up of 15 months (range, 0 to 54 months). There were no complications.
Conclusions:
IGCNB performed under a standard protocol is effective and safe and should be considered as an initial diagnostic tool for the evaluation of lymphadenopathy suspicious for lymphoma.
